Reported NPAT up 62% but underlying profit rose just 11% as net debt climbed...

What changed

Revenue rose 14.0% to NZ$272.2m and PBT rose 59.4% to NZ$422.5m, with NPAT up 62.2% to NZ$436.3m. The gap between reported NPAT and the company's preferred underlying profit measure is stark: underlying profit was NZ$190.3m, up only 11.0% on FY22. Operating cash flow grew 7.9% to NZ$398.2m, capex was NZ$56.1m (20.6% of revenue), and pre-lease free cash flow lifted to NZ$342.1m from NZ$317.5m. The balance sheet expanded 18.9% to NZ$6.94b in assets; gross borrowings rose 31.4% to NZ$1.39b while cash fell 50.1% to NZ$12.6m, taking estimated net debt to NZ$1.38b (from NZ$1.04b). Occupation right sales rose 10% to 1,103, and development margin expanded to 31.6% from 29.7%. The final dividend was lifted to 13.2 cps from 11.6 cps.

What matters

• Two different earnings narratives. Statutory NPAT growth of 62.2% is driven largely by non-cash fair-value movements typical for retirement village operators; the company's own underlying profit measure grew only 11.0%. Operating cash flow growth of 7.9% is closer to the underlying figure than to NPAT.
• Leverage is weakening. Gross borrowings rose NZ$333.0m and cash fell NZ$12.7m, lifting estimated net debt by roughly NZ$345.7m (+33.4%) while equity grew 18.8%. Pre-lease FCF of NZ$342.1m broadly covered the net-debt increase, but the balance sheet is clearly funding expansion rather than deleveraging.
• Cash conversion deteriorated. Pre-lease FCF/NPAT fell to 78.4% from 118.1%. That is mechanical (NPAT inflated by fair-value gains), but it is a reminder that the reported headline overstates the cash underpinning of the result.

Expectations

No forward-work pipeline, FY24 guidance, or explicit quantitative target was disclosed in the supplied release, so the result cannot be benchmarked against management expectations. The H1/H2 shape is informative: HY23 contributed 47.1% of full-year revenue but only 30.5% of full-year NPAT, implying an implicit second-half NPAT of NZ$303.3m versus NZ$133.1m in the first half. Second-half revenue of NZ$144.0m vs NZ$128.2m in H1 is a more modest skew, reinforcing that the NPAT shape is driven by revaluation timing rather than operating cadence.

Quality of result

The operating core of the result looks solid but more incremental than the headline suggests. Unit sales +10%, revenue +14%, and development margin up ~190bps all point to a genuinely improving operating business, and the underlying profit +11.0% is the best read on that. However, the 62.2% NPAT jump is not an operating result of that magnitude: it reflects investment-property fair-value accounting and a tax credit (effective tax rate of about -3.3% in FY23 vs -1.5% in FY22), so PBT growth of 59.4% is the cleaner measure than NPAT, and underlying profit growth of 11.0% is the cleaner measure than either. Cash conversion versus NPAT has clearly weakened, and net debt has stepped up sharply to fund growth. Receivable days were effectively flat at ~7 days, so the result is not being assisted by working capital.

Unresolved

• No reconciliation between statutory NPAT of NZ$436.3m and underlying profit of NZ$190.3m was captured in the excerpts, so the quantum of fair-value and other adjustments cannot be verified.
• No explicit net-debt/EBITDA, interest cover, or covenant headroom disclosure is available despite the sharp rise in gross borrowings.
• No forward-work (landbank, units under construction, or build pipeline) or FY24 settlement guidance was disclosed, leaving the earnings trajectory unanchored.
• Segment, geographic, and concentration data were not provided, and NTA per share was not disclosed, so valuation context (P/NTA) cannot be computed.

This briefing cannot assess management's underlying profit reconciliation, covenant headroom, or the outlook for development settlements because none of those items were included in the supplied extraction.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.